JUN and hepatocellular carcinoma: Phospho-c-Jun staining in HCC is associated with poor response to sorafenib[46], the only drug currently approved for treatment of advanced HCC[1], underscoring the importance of identifying more effective therapies for HCCs with JNK activation.